Exact Sciences Corp. stock (US30063P1057): Q4 earnings miss with revenue growth

Exact Sciences Corp. reported Q4 earnings of -$0.21 per share, missing estimates by $0.29, though revenue rose 23.1% year-over-year, per MarketBeat data from February 13.

Exact Sciences Corp. released its latest quarterly earnings on February 13, reporting earnings per share of ($0.21), which fell short of analyst expectations of $0.08 by $0.29. Revenue for the period increased 23.1% on a year-over-year basis, reflecting continued demand for its cancer screening products. The results were published by MarketBeat as of February 13.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Exact Sciences Corporation
• Sector/industry: Healthcare / Molecular Diagnostics
• Headquarters/country: Madison, Wisconsin, USA
• Core markets: United States, Europe
• Key revenue drivers: Cancer screening tests like Cologuard
• Home exchange/listing venue: Nasdaq (EXAS)
• Trading currency: USD

Exact Sciences Corp.: core business model

Exact Sciences Corp. focuses on molecular diagnostics for early cancer detection and prevention. Headquartered in Madison, Wisconsin, the company develops non-invasive tests targeting colorectal and other cancers. Its flagship product, Cologuard, is a stool-based DNA test approved for average-risk colorectal cancer screening. The company reported annual sales of $3.25 billion as of the latest data published by MarketBeat.

This model emphasizes precision medicine, leveraging genetic and epigenetic markers to improve screening accuracy over traditional methods. Exact Sciences serves primarily the US market, where colorectal cancer remains a leading cause of death, making its tests relevant for millions of patients and providers.

Main revenue and product drivers for Exact Sciences Corp.

Cologuard drives the majority of revenue, with strong adoption among primary care physicians and health systems. The test's revenue contribution supported the 23.1% quarterly growth reported on February 13. Additional products include Oncotype DX for breast cancer risk assessment and emerging tests in multi-cancer detection. Key drivers include reimbursement expansions from Medicare and private insurers, boosting accessibility for US patients.

Research and development investments fuel pipeline growth, with over $1.27 per share in cash flow noted in trailing twelve months data from MarketBeat. The company's net margins stood at -6.40% for the period ending in the latest report, reflecting high R&D and marketing spend typical in diagnostics.

Industry trends and competitive position

The molecular diagnostics sector benefits from rising cancer incidence and screening guidelines emphasizing non-invasive options. Exact Sciences holds a leading position in US colorectal screening, with Cologuard capturing significant market share post-FDA approval. Competitors include Guardant Health and Natera, but Exact Sciences' established reimbursement gives it an edge for retail investors tracking US healthcare exposure.

Why Exact Sciences Corp. matters for US investors

Listed on Nasdaq, Exact Sciences offers direct exposure to the $50+ billion US cancer diagnostics market. Its focus on preventive screening aligns with aging demographics and policy shifts toward early detection, key for portfolios emphasizing healthcare innovation amid US economic growth.

Conclusion

Exact Sciences Corp. demonstrated revenue resilience with 23.1% growth despite an earnings miss in its February 13 report. Ongoing product adoption and R&D position it in a high-growth diagnostics niche, though profitability challenges persist. Investors monitoring US healthcare trends will note its market cap of $20.03 billion and analyst price target of $92.13 as of recent data.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.